MB 110

Drug Profile

MB 110

Alternative Names: DBPR 110; MB-110; NSFA 10003S0

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator MICROBIO Group
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis C

Most Recent Events

  • 06 Oct 2016 MICROBIO has patent protection for MB 110 in Australia
  • 28 Apr 2016 Phase-I clinical trials in Hepatitis C in Taiwan (PO) before April 2016
  • 28 Apr 2016 Phase-I clinical trials in Hepatitis C in USA (PO) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top